Business Context and Reporting Period
This Form 8-K filing by Cytomx Therapeutics, Inc. (CTMX) reports on corporate governance changes effective May 22, 2019. The company is a biopharmaceutical firm incorporated in Delaware and listed on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of CFO: Debanjan Ray resigned as Chief Financial Officer, principal financial officer, and principal accounting officer, effective May 15, 2019.
- Appointment of PFO: Dr. Sean McCarthy, Chairman and CEO, was designated to assume the responsibilities of principal financial officer effective May 22, 2019.
- Appointment of PAO: Robin Knifsend, Vice President of Finance, was designated to assume the responsibilities of principal accounting officer effective May 22, 2019.
Management Commentary and Risks
Management confirmed there are no family relationships between the newly designated officers and any directors or executive officers. Additionally, no relationships or related party transactions requiring disclosure exist between these officers and the company. The filing notes Ms. Knifsend's extensive background in finance within the pharmaceutical and life sciences sectors, including roles at Actelion, Janssen, and Maxygen.
Investor Verification Checklist
- Verify the effective dates of the CFO resignation and subsequent officer appointments.
- Review the Company's proxy statement filed on April 26, 2019, for Dr. McCarthy's full biographical data.
- Confirm the absence of undisclosed related party transactions involving the new financial leadership.
- Monitor future filings for the appointment of a permanent Chief Financial Officer, as the CEO is currently serving in an interim capacity.